Marker Therapeutics (NASDAQ:MRKR) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Marker Therapeutics (NASDAQ:MRKR) from a sell rating to a hold rating in a research report report published on Saturday morning.

A number of other brokerages have also recently commented on MRKR. Zacks Research raised Marker Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, November 18th. HC Wainwright initiated coverage on shares of Marker Therapeutics in a report on Monday, December 8th. They set a “buy” rating and a $10.00 price objective for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Marker Therapeutics in a research note on Monday, December 22nd. Finally, UBS Group reiterated a “buy” rating on shares of Marker Therapeutics in a report on Monday, December 8th. Three equities research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $10.17.

Marker Therapeutics Stock Performance

Shares of Marker Therapeutics stock opened at $1.79 on Friday. The firm has a fifty day moving average of $1.21 and a two-hundred day moving average of $1.21. The stock has a market capitalization of $29.84 million, a price-to-earnings ratio of -1.46 and a beta of 1.37. Marker Therapeutics has a 52 week low of $0.81 and a 52 week high of $4.07.

Marker Therapeutics (NASDAQ:MRKR) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.57. Marker Therapeutics had a negative return on equity of 92.35% and a negative net margin of 304.56%.The business had revenue of $1.23 million during the quarter, compared to analysts’ expectations of $0.72 million. As a group, research analysts forecast that Marker Therapeutics will post -0.65 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. Jane Street Group LLC acquired a new position in shares of Marker Therapeutics in the second quarter valued at approximately $33,000. Virtu Financial LLC bought a new stake in Marker Therapeutics in the 3rd quarter valued at $25,000. Finally, Two Sigma Investments LP acquired a new position in Marker Therapeutics in the 3rd quarter worth $33,000. Institutional investors own 22.39% of the company’s stock.

About Marker Therapeutics

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.